Literature DB >> 1381946

Detection of RAS mutations in archival testicular germ cell tumors by polymerase chain reaction and oligonucleotide hybridization.

J W Moul1, S M Theune, E H Chang.   

Abstract

Preliminary studies of RAS mutational activation in human testicular germ cell neoplasms have yielded conflicting results. Whereas two studies of clinical material revealed a significant incidence of N- and KRAS mutations, two studies of a variety of germ cell lines failed to document RAS mutations. To clarify the incidence of RAS mutations in these tumors, we studied archival paraffin-embedded, formalin-fixed orchiectomy specimens from 25 nonseminomas (NSGCT), 18 seminomas (SEM), and one Leydig cell tumor. For 14 of the 44 neoplasms, DNA was also available from nonmalignant testis adjacent to the tumor. Six age-matched patients had testes removed because of nonmalignant disease and were studied as controls. Polymerase chain reaction (PCR) amplified the K-, N-, and HRAS 12, 13, and 61 codons of these specimens, and mutations were detected with mutation-specific oligonucleotide probe hybridization of Southern and slot blots. Four mutations were found in KRAS 12 (4/44;[9.1%]). One seminoma [1/18(5.6%)] contained the mutation GGT(GLY)----CGT(ARG), and three NSGCT [3/25(12%)] were found to have GGT(GLY)----GAT(ASP) mutations. One of the NSGCT mutations was detected in adjacent nonmalignant tissue, but the corresponding tumor did not contain any detectable mutation. No mutations were detected at KRAS 13 or 61, in NRAS or HRAS 12, 13, or 61, or in the control normal testes. PCR, slot blots, and hybridizations were performed twice by two separate investigators for confirmation of results. PCR-generated mutation-specific positive controls were created for all possible RAS mutations, and these along with wild-type DNA controls were integral to interpretation of the oligonucleotide mismatch hybridization assay. By using positive and negative controls, we have detected a relatively low incidence of RAS mutations in archival human testicular germ cell tumors.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1381946     DOI: 10.1002/gcc.2870050204

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  11 in total

1.  Restricted 12p amplification and RAS mutation in human germ cell tumors of the adult testis.

Authors:  H Roelofs; M C Mostert; K Pompe; G Zafarana; M van Oorschot; R J van Gurp; A J Gillis; H Stoop; B Beverloo; J W Oosterhuis; C Bokemeyer; L H Looijenga
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

2.  Activating mutations and/or expression levels of tyrosine kinase receptors GRB7, RAS, and BRAF in testicular germ cell tumors.

Authors:  Alan McIntyre; Brenda Summersgill; Hayley E Spendlove; Robert Huddart; Richard Houlston; Janet Shipley
Journal:  Neoplasia       Date:  2005-12       Impact factor: 5.715

Review 3.  Zebrafish Germ Cell Tumors.

Authors:  Angelica Sanchez; James F Amatruda
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

4.  K-RAS and N-RAS mutations in testicular germ cell tumors.

Authors:  Bekir Muhammet Hacioglu; Hilmi Kodaz; Bulent Erdogan; Ahmet Cinkaya; Ebru Tastekin; Ilhan Hacibekiroglu; Esma Turkmen; Osman Kostek; Ezgi Genc; Sernaz Uzunoglu; Irfan Cicin
Journal:  Bosn J Basic Med Sci       Date:  2017-05-20       Impact factor: 3.363

Review 5.  Treatment of clinical stage I testicular cancer and a possible role for new biological prognostic parameters.

Authors:  C Bokemeyer; M A Kuczyk; J Serth; J T Hartmann; H J Schmoll; U Jonas; L Kanz
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

Review 6.  Molecular biology of testicular germ cell tumors: current status.

Authors:  B Schmidt; R Ackermann; T Strohmeyer
Journal:  J Mol Med (Berl)       Date:  1995-07       Impact factor: 4.599

7.  hH-Rev107, a class II tumor suppressor gene, is expressed by post-meiotic testicular germ cells and CIS cells but not by human testicular germ cell tumors.

Authors:  S Siegrist; C Féral; M Chami; B Solhonne; M G Mattéi; E Rajpert-De Meyts; G Guellaën; F Bulle
Journal:  Oncogene       Date:  2001-08-23       Impact factor: 9.867

Review 8.  Clinical relevance of KRAS in human cancers.

Authors:  Sylwia Jancík; Jirí Drábek; Danuta Radzioch; Marián Hajdúch
Journal:  J Biomed Biotechnol       Date:  2010-06-07

9.  EGF Receptor and mTORC1 Are Novel Therapeutic Targets in Nonseminomatous Germ Cell Tumors.

Authors:  Kenneth S Chen; Nicholas J Fustino; Abhay A Shukla; Emily K Stroup; Albert Budhipramono; Christina Ateek; Sarai H Stuart; Kiyoshi Yamaguchi; Payal Kapur; A Lindsay Frazier; Lawrence Lum; Leendert H J Looijenga; Theodore W Laetsch; Dinesh Rakheja; James F Amatruda
Journal:  Mol Cancer Ther       Date:  2018-02-26       Impact factor: 6.261

10.  Association between the estrogen receptor alpha A908G mutation and outcomes in invasive breast cancer.

Authors:  Matthew H Herynk; Irma Parra; Yukun Cui; Amanda Beyer; Meng-Fen Wu; Susan G Hilsenbeck; Suzanne A W Fuqua
Journal:  Clin Cancer Res       Date:  2007-06-01       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.